Emmanouil Aerakis received his Bachelor’s degree in Molecular
Biology and Genetics from the Democritus University of Thrace in
2018, supported by an IKY fellowship. In 2020, he completed his
Master’s in Molecular and Applied Physiology at the University of
Athens Medical School, graduating with distinction. Since 2021, he
has been pursuing his PhD at the Biomedical Sciences Research
Center "Alexander Fleming" in the group of Professor Maria
Tsoumakidou, supported by an HFRI scholarship. His research focuses
on the spatio-temporal regulation of type I dendritic cells in cancer,
using in vivo and in vitro models, gene-editing techniques, multicolor flow cytometry,
immunofluorescence, and ex vivo human assays. In 2025, he was awarded a Bodossaki
Foundation fellowship and joined the group of Professor Miriam Merad at the Department of
Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai. He has received
awards at national and international conferences and authored two publications. Since 2025,
he has been working with OncoGenesys as a Molecular Biologist supporting target
validation, assay development, and screening strategies for the company’s drug discovery and
screening pipelines.

Alexios N. Matralis holds a B.Sc. in Chemistry from the University of Patras and both an M.Sc. and Ph.D. in Medicinal Chemistry from the University of Athens. He has over fifteen years of research experience in the development of bioactive molecules targeting multifactorial human diseases such as atherosclerosis, type 2 diabetes, cancer, chronic inflammatory disorders, and malaria. Following his Ph.D., he conducted postdoctoral research at McGill University in Montréal, Canada, where he developed a novel series of senescence-inducing agents for pancreatic cancer, which attracted interest from Merck for further development. In 2017, he joined GlaxoSmithKline as a senior researcher, where he contributed to the development of novel fast-acting antimalarial compounds, currently undergoing advanced preclinical studies. In 2018, Alexios joined BSRC “Alexander Fleming” as a Stavros Niarchos Research Fellow where he led research programs focused on small molecule drug discovery targeting fibrosis, cancer, and inflammatory diseases, including an Individual Research Grant from the Hellenic Foundation for Research and Innovation. Since 2025, Alexios serves as Medicinal Chemist Consultant at OncoGenesys, overseeing the development of novel cancer therapeutics.

Antreas Afantitis, PhD, MBA is the Founder of NovaMechanics and the Scientific Director of the Entelos Institute. He has a strong scientific background in chem-, bio-, and nanoinformatics, as well as in modeling, simulation, and medicinal and materials chemistry. His work has been published in over 140 original research articles and reviews in international peer-reviewed journals. According to Google Scholar, his h-index exceeds 44, and he is ranked among the world’s top 2% of scientists on the Stanford list. He has successfully coordinated applied drug discovery projects, which have led to the filing of three patents. At NovaMechanics Ltd, he has led the development and implementation of state-of-the-art IT systems—including databases, web services, and custom scientific software—addressing challenges in cheminformatics, bioinformatics, nanoinformatics, modeling, simulation, and big data analysis. He has overseen all R&D activities and product development of the company, including the Isalos Analytics Platform, Enalos+ KNIME nodes, Enalos Cloud Platform, and Enalos Suite. He also participates as Principal Investigator in more than 40 multi-partner international research projects. Since 2025, Antreas has been serving as a Cheminformatics Consultant at OncoGenesys, where he oversees the design of novel small molecules targeting cancer.